Skip to content

Beam Therapeutics

US · BEAM #2614 by market cap Listed 2020
20.90 -0.04 -0.19%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 14 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.8 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
114.04% +1.81pp
Institutions
325 -14
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund78.76%
Hedge Fund18.58%
VC/PE Fund9.59%
Public Company4.23%
Private Company1.88%
Individual/Insider1.36%
Government Pension Fund0.51%
Family Office/Trust0.25%
Insurance Company0.23%

Top holders as of 2026-09-30

FMR 12.11% · 12.07M sh
ARK Investment Management LLC 11.84% · 11.81M sh
Farallon Capital Management, L.L.C. 10.27% · 10.24M sh
BlackRock 9.15% · 9.12M sh
State Street Global Advisors 5.94% · 5.92M sh
Vanguard Portfolio Management, LLC 4.92% · 4.90M sh
Vanguard Capital Management, LLC 4.62% · 4.61M sh
Arch Venture Partners, L.P. 4.56% · 4.54M sh
Amova Asset Management 3.46% · 3.46M sh
T. Rowe Price Group, Inc. 3.43% · 3.42M sh
Sumitomo Mitsui Trust Asset Management 3.35% · 3.35M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 19 buys · 31 sells

NameRoleStake
FMR -- 12.11%
John Evans Chief Executive Officer 0.95%
Giuseppe Ciaramella President 0.17%
Christine Bellon Chief Legal Officer 0.11%
Robert Taylor Nelsen Former Independent Director 0.06%
Mark Fishman Lead Independent Director 0.02%
Bethany Cavanagh Senior VP of Finance, Treasurer & Principal Accounting Officer 0.01%
Sravan Emany Chief Financial Officer 0.01%
Amy Simon Chief Medical Officer 0.00%
John Michael Maraganore Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-10-15 John Evans Chief Executive Officer Derivative Exercise and Sale -50,000 $1.03–23.98
2026-10-15 John Evans Chief Executive Officer Intent to Sell (Form 144) -25,000 $23.98
2026-10-14 John Evans Chief Executive Officer Intent to Sell (Form 144) -25,000 $23.57
2026-09-30 Bethany Cavanagh Senior VP of Finance, Treasurer & Principal Accounting Officer Automatic Disposition -187 $24.41
2026-09-23 Giuseppe Ciaramella President Other Disposition -123,407 --
2026-07-26 Amy Simon Chief Medical Officer Automatic Disposition -16,667 $25.74
2026-06-29 John Evans Chief Executive Officer Derivative Exercise and Sale -50,000 $0.67–35.91
2026-06-29 John Evans Chief Executive Officer Intent to Sell (Form 144) -25,000 $34.31
2026-06-29 Amy Simon Chief Medical Officer Automatic Disposition -373 $34.73
2026-06-28 John Evans Chief Executive Officer Intent to Sell (Form 144) -25,000 $35.49
2026-06-16 Giuseppe Ciaramella President Derivative Exercise and Retained +35,505 $0.67–1.03
2026-06-02 John Michael Maraganore Independent Director Other Derivative Acquisition +19,676 $29.55
2026-06-02 Mark Fishman Lead Independent Director Other Derivative Acquisition +19,676 $29.55
2026-06-02 Graham Cooper Independent Director Other Derivative Acquisition +19,676 $29.55
2026-06-02 Kathleen Walsh Independent Director Other Derivative Acquisition +19,676 $29.55
2026-06-02 Chirfi Guindo Independent Director Other Derivative Acquisition +19,676 $29.55
2026-06-02 Christi Shaw Independent Director Other Derivative Acquisition +19,676 $29.55
2026-04-13 Carole Ho Former Independent Director Intent to Sell (Form 144) -87,784 $30.73
2026-04-01 Christine Bellon Chief Legal Officer Intent to Sell (Form 144) -20,000 $21.90
2026-04-01 John Evans Chief Executive Officer Intent to Sell (Form 144) -66,874 $21.90

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:41 · For reference only, not investment advice and not tailored to your situation.

Beam Therapeutics discussion 0 comments

Add a comment